Background: The natural history of adult liver disease due to a1-antitrypsin deficiency (A1AD) remains poorly understood. Objective: We investigated whether heterozygosity for the Z-allele predisposes for the development of clinically significant portal hypertension (CSPH). Moreover, we aimed to non-invasively assess the prevalence of liver fibrosis and hepatic steatosis in adults with A1AD treated by pulmonologists. Methods: SERPINA1 rs28929474 (Z-allele) was genotyped in 315 patients with CSPH (hepatic venous pressure gradient !10 mmHg; cases) and 248 liver donors (controls). In addition, 31 adults with A1AD (Pi*ZZ/Pi*SZ) and 11 first-degree relatives (Pi*MZ/Pi*MS) underwent liver stiffness and controlled attenuation parameter (CAP) measurement. Results: Heterozygosity for the Z-allele was observed in 6.7% of patients with CSPH and 2.8% of liver donors. Thus, harboring the Z-allele was associated with increased odds of CSPH (odds ratio: 2.47; 95% confidence interval: 1.03-5.9; P ¼ 0.042). Among Pi*ZZ/Pi*SZ patients, 23%/3% had liver stiffness values indicative of liver fibrosis ( !F2/ !F3). Interestingly, 65%/52% of Pi*ZZ/Pi*SZ patients had CAP values indicative of hepatic steatosis ( !S1/ !S2). Conclusions: Heterozygosity for the Z-allele predisposes for the development of CSPH, confirming its role as a genetic (co)factor in liver disease. Pi*ZZ/SZ patients rarely develop liver fibrosis !F3 during adulthood; however, liver fibrosis !F2 is common. Elevated CAP values hint at underlying hepatic steatosis, which might promote liver fibrosis progression.
Introduction a1-antitrypsin deficiency (A1AD) is a consequence of misfolding and intracellular polymerization of mutant a1-antitrypsin within the endoplasmic reticulum (ER) of hepatocytes (toxic gain-of-function), which induces a proinflammatory and fibrogenic response by nuclear factor-jB activation. Moreover, A1AD increases the sensitivity to ER stress in the presence of concomitant liver diseases. 1 In contrast, the lack of a1-antitrypsin in the lung (loss-of-function) leads to early-onset panlobular basal emphysema, the typical manifestation of A1AD.
A1AD is one of the most common genetic disorders, since about 1:25 European Caucasians harbor at least one Z-allele (SERPINA1 rs28929474 [T] ). About 1:2000 is homozygous for the Z-allele (Pi*ZZ). While the pulmonary manifestation of A1AD has been intensively studied, the natural history of adult liver disease due to A1AD remains poorly understood.
In 1986, Eriksson and co-workers observed cirrhosis in about one-third of autopsied patients with the Z phenotype (i.e. mostly Pi*ZZ genotype). 2 Based on these and other observations, A1AD is considered a separate aetiological entity. 1 However, until recently, liver biopsy was the only method for assessing the extent of hepatic involvement. Since liver biopsy is limited by its invasiveness, it is mostly performed in patients with findings suggestive of advanced chronic liver disease (ACLD), and thus, biopsy series in these referral populations might substantially overestimate the risk of liver fibrosis/cirrhosis. Population-based surveys, on the other hand, only capture the tip of the iceberg (e.g. patients who have already progressed to ACLD), rather than providing information on the complete spectrum of sub-clinical liver involvement. 3, 4 Promising treatment approaches are currently moving from preclinical to clinical development. 5 Thus, it is of high relevance that we improve our understanding of the natural history of this condition and identify patients who have already developed significant liver fibrosis, in order to facilitate the design of such clinical trials.
Besides Pi*ZZ patients, heterozygosity for the Z-allele might be a genetic (co)factor for the development of ACLD. [6] [7] [8] [9] However, this association has not been observed throughout all aetiologies/cohorts, and thus, more data is required to facilitate genetic counselling. 10, 11 In a genetic sub-study (case-control design), we investigated whether heterozygosity for the Z-allele predisposes for the development of ACLD, as indicated by the presence of clinically significant portal hypertension (CSPH).
Moreover, we assessed thoroughly characterized A1AD patients treated by pulmonologists (Pi*ZZ/ Pi*SZ) as well as their first-degree relatives (Pi*MZ/ Pi*MS) by transient elastography (TE) with controlled attenuation parameter (CAP) measurement, a wellvalidated non-invasive method for the assessment of liver fibrosis and hepatic steatosis.
Patients and methods

Sub-studies
In sub-study I, the SERPINA1 rs28929474(T) (Z-allele) was genotyped in 315 patients who were diagnosed with CSPH at the Medical University of Vienna between 2004 and 2014 (cases) and 248 donors from liver transplantations performed at the Medical University of Innsbruck (controls).
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In sub-study II, 31 adults with A1AD (Pi*ZZ/Pi*SZ) and 11 first-degree relatives (Pi*MZ/Pi*MS) underwent liver stiffness and CAP measurement within a prospective study in 2015/2016. Patients were identified based on a registry of subjects with A1AD treated by pulmonologists and directly contacted by the investigators. 13 Please see the Supplementary material for information on hepatic venous pressure gradient (HVPG) measurement and SERPINA1 genotyping (sub-study I), as well as liver stiffness and CAP measurement, laboratory tests, the short form (36) health survey (SF-36), and the alcohol use disorders identification test (AUDIT) (sub-study II).
Results
Sub-study I
Characteristics of patients with CSPH. Most patients were male (73.9% (232/314)) with a median age of 52.7 (16) years. Hepatitis C (47.8% (150/314)), alcoholic liver disease (31.2% (98/314)), and non-alcoholic fatty liver disease (NAFLD) (7.3% (23/314)) were the most common aetiologies. The prevalence of diabetes was 19.4% (61/314). The patients had a median HVPG of 17 (8) mmHg and a median model for end-stage liver disease score of 10 (6.8) points.
After excluding one Pi*ZZ patient who underwent liver transplantation, 6.7% (21/314) of patients with CSPH were heterozygous for the Z-allele.
Except for aetiology of liver disease, a comparison of patients with and without the Z-allele revealed no statistically significant differences (Table 1) . Interestingly, the Z-allele was overrepresented in patients with cryptogenic cirrhosis when compared to patients with known aetiology (33.3% (3/9) vs. 5.9% (18/305); P ¼ 0.017).
Comparison of the proportions of patients heterozygous for the Z-allele. Among liver donors, 2.8% (7/248) were heterozygous for the Z-allele (P ¼ 0.049 vs. CSPH), which is similar to the expected frequency in the Austrian population (Figure 1 ). Harboring the Z-allele increased the odds of CSPH (odds ratio: 2.47, 95% confidence interval: 1.03-5.9; P ¼ 0.042).
Sub-study II Enrollment. Forty-two A1AD index patients treated by pulmonologists (Pi*ZZ/SZ) were informed about the study. Among these, 31 patients (73.8%) agreed to participate in sub-study II. In addition, 11 first-degree relatives (Pi*MZ/MS) were enrolled. Patient characteristics. Please see Table 2 and the Supplementary material for patient characteristics.
Liver stiffness. Liver stiffness was comparable between Pi*ZZ/Pi*SZ patients (5.77 AE 0.3 kPa) and their firstdegree relatives (Pi*MZ/MS; 5.36 AE 0.6 kPa; P ¼ 0.518; Figure 2 ). Among Pi*ZZ/Pi*SZ patients, 22.6% (7/31) and 3.2% (1/31) had liver stiffness values indicative of liver fibrosis !F2 and !F3, respectively (Figure 3 ).
Risk factors for liver fibrosis !F2. Combining all subjects included in sub-study II, subjects with liver fibrosis !F2 had higher body mass index (BMI; 27.6 AE 1.4 vs. 24.5 AE 0.7 kg Â m À2 ; P ¼ 0.049) and serum gammaglutamyltransferase levels (GGT; 45 (62) vs. 27 (19) U/L; P ¼ 0.013) ( Table 2 ). In contrast, lower serum high-density lipoprotein (HDL) cholesterol levels (50.1 AE 4.1 vs. 66.2 AE 2.9 mg Â dL À1 ; P ¼ 0.014) were observed in the liver fibrosis !F2 group. Moreover, we observed trends towards a higher prevalence of hepatic steatosis !S1 (87.5% (7/8) vs. 53% (18/34); P ¼ 0.078) and !S2 (75% (6/8) vs. 35.3% (12/34); P ¼ 0.078), as well as higher HOMA-IR (homeostatic model assessment of insulin resistance) levels (3.31 (2.61) vs. 2.01 (1.99) mg Â mU Â dL À1 Â mL À1 ; P ¼ 0.107) in subjects with liver fibrosis !F2. As expected, subjects with liver fibrosis !F2 showed lower platelet counts (174 (23) vs. 221(83) G Â L À1 ; P < 0.001).
If analysed as a continuous variable, liver stiffness tended to correlate with the same parameters (Supplementary Table 2) .
CAP values. Pi*ZZ/Pi*SZ patients had numerically higher CAP values (267 AE 9 dB Â m À1 ) than their firstdegree relatives (Pi*MZ/MS; 237 AE 22 dB Â m Table 2 ). We observed direct correlations with high-sensitive C-reactive protein (hsCRP; q ¼ 0.418; P ¼ 0.008) as a marker of inflammation, and von Willebrand factor antigen (vWF; q ¼ 0.451; P ¼ 0.003) as a marker of endothelial dysfunction. Moreover, CAP tended to correlate positively with liver stiffness (q ¼ 0.304; P ¼ 0.053).
Concomitant liver diseases. Overall, only three subjects (7.1% (3/42)) reported at-risk drinking (AUDIT !8 points); however, serum carbohydrate-deficient transferrin levels were < 2.6% in all individuals (Table 2 ).
14 Three subjects (7.1% (3/42)) were hepatitis B surfaceand core antibody-positive, while we did not observe hepatitis B surface antigen positivity. There was no evidence of other chronic liver diseases.
Please see the Supplementary material for information on hepatitis A/B vaccination and hepatitis E seroprevalence, as well as health-related quality of life.
Discussion
To assess the role of the Z-allele as a genetic (co)factor for the development of ACLD, we investigated whether heterozygosity for the Z-allele predisposes for the development of CSPH (sub-study I). Harboring the Z-allele was associated with approximately 2.5-fold increased odds of CSPH. This might be explained by the impact of A1AD on hepatic inflammation and fibrosis. 1 Interestingly, the Z-allele was overrepresented in patients with cryptogenic cirrhosis (33.3%) when compared to patients with known aetiology (5.9%). This confirms a previous report of Graziadei et al., who observed a prevalence of 26.9% in patients who underwent liver transplantation for cryptogenic cirrhosis. 7 Thus, heterozygosity for the Z-allele might have implications in patients without a known aetiology. This prompts SERPINA1 genotyping in patients with cryptogenic cirrhosis, as well as in patients with findings indicative of an otherwise unexplained chronic liver disease. The group of patients with cryptogenic cirrhosis might have comprised a considerable proportion of NAFLD patients (i.e. 'burnt-out nonalcoholic steatohepatitis'); however, a previous study did not observe a link between A1AD alleles and liver fibrosis in NAFLD. [15] [16] [17] Moreover, we did not observe an overrepresentation of the Z-allele in NAFLD patients. Since sub-study I confirmed the role of the Z-allele as a genetic (co)factor for the development of ACLD, we evaluated thoroughly characterized a1-antitrypsin-deficient patients treated by pulmonologists (Pi*ZZ/Pi*SZ) as well as their first-degree relatives (Pi*MZ/Pi*MS) by TE with CAP to further investigate the relationship between A1AD genotype and liver phenotype (sub-study II).
In sub-study II, we observed a low prevalence of liver fibrosis !F3 ( !9.5 kPa; 3.2%), although about one-quarter of patients showed liver stiffness values indicative of liver fibrosis !F2 ( !7.1 kPa; 22.6%). Interestingly, the prevalence of liver fibrosis !F3 in our study was considerably lower than the proportion of patients with ACLD reported by previous studies. 2, 18 In the only prospective study performing biopsies to investigate liver involvement in Pi*ZZ patients (n ¼ 57), Dawwas et al. observed liver fibrosis !F3 in 17.5% of the overall study population. 18 Liver biopsies were only performed in patients with clinical, laboratory or radiological evidence of liver injury, and some patients declined liver biopsy. Thus, the authors might have even underestimated the prevalence of liver fibrosis !F3 in their cohort, since the diagnosis might have been missed in patients with sub-clinical liver disease who were not referred for liver biopsy. Mean/median age and BMI were very similar to our study and the authors reported a high participation rate of 89%, which limits the risk of selection bias. Therefore, the different study settings seem to be the only plausible explanation for the discrepancy in the proportion of patients with liver fibrosis !F3: Dawwas and coworkers recruited study participants among patients referred to the respiratory clinic of a tertiary care centre. 18 In contrast, the Pi*ZZ/SZ patients included in our study were identified based on a registry of subjects with A1AD treated by pulmonologists and directly contacted by the investigators. 13 Since our study was not restricted to patients treated at a tertiary care centre, our study population is presumably more representative for the overall population of Pi*ZZ/SZ patients.
Another recently published study used acoustic radiation force impulse (ARFI) elastography, a noninvasive method that is less commonly applied than TE. 19, 20 Importantly, ARFI was performed in only 39.5% of the study population, which puts this study at particularly high risk of selection bias. Moreover, the proportion of study participants with liver stiffness values suggestive of liver fibrosis !F2 was comparable between Pi*ZZ (25%) and Pi*MM subjects (22%), which questions the reliability of the measurements. Of note, study participants were fasted for only 3 h and liver stiffness assessed by ARFI elastography has been shown to remain numerically increased, even 3 h after a meal intake. 21 Kim and colleagues performed liver biopsies in a small series (n ¼ 11) of Pi*ZZ patients to investigate the value of magnetic resonance elastography for liver fibrosis. 22 The proportion of patients with liver fibrosis !F2 was 18.2%, which is very similar to our study. However, the small sample size and the strict in-and exclusion criteria substantially limit the conclusions that can be drawn from this study. Nevertheless, its results support the use of non-invasive methods in patients with A1AD, since the diagnostic performance in A1AD was comparable to NAFLD patients who served as a control group.
Interestingly, in our study, about two-thirds of Pi*ZZ/Pi*SZ patients had CAP values indicative of hepatic steatosis !S1. This is in line with the histological results of Dawwas et al., which observed hepatic steatosis in 87.5% of patients who underwent liver biopsy (i.e. the sub-group of patients with evidence of liver injury). 18 Importantly, subjects with liver fibrosis !F2 had higher BMI and GGT levels, and also tended to show higher CAP values. Of note, a recent meta-analysis based on individual patient data demonstrated that high CAP is not associated with a systematic overestimation of liver fibrosis by TE. 23 CAP itself was linked to a series of metabolic parameters such as BMI, HbA1c and HOMA-IR. Moreover, we observed direct correlations with hsCRP and vWF. To summarize these findings, hepatic steatosis, which can be assessed non-invasively by CAP, seemed to be associated with more advanced liver disease, and also several cardiovascular risk factors. These findings underline that, similar to NAFLD, lifestyle interventions might be of high relevance in patients with A1AD. As clinical studies on specific treatment approaches are still ongoing, it appears reasonable to counsel A1AD patients with hepatic steatosis in analogy to the NAFLD population, 24 although some measures might be complicated by the underlying pulmonary manifestation.
Except for three subjects reporting at-risk drinking (however, none of them had liver stiffness values indicative of liver fibrosis !F2), there was no evidence of concomitant liver diseases.
Interestingly, less than one-third of Pi*ZZ/Pi*SZ patients were vaccinated against hepatitis A/B (Supplementary material). Even in the sub-group of patients on a1-antitrypsin augmentation therapy, only half of the patients were vaccinated, although vaccination is recommended by the label since it is a plasma derivative. Thus, it will require the combined efforts of pulmonologists and hepatologists to increase vaccination rates in this patient population.
Several limitations should be considered when interpreting the findings of our study. First, not all contacted patients (73.8%) participated in our study. However, most patients declined to participate for logistical reasons (e.g. distance to the study center). Moreover, liver stiffness/CAP measured by TE has not been validated against liver biopsy in patients with A1AD. However, its diagnostic value has been confirmed in most aetiologies of chronic liver disease, including NAFLD. [24] [25] [26] All relevant confounding factors for the TE-based assessment of liver fibrosis induce false-high liver stiffness results leading to an overestimation of liver fibrosis stage. 27 Thus, they cannot explain the very low prevalence of liver fibrosis !F3 observed in our study. Since sample size limits the conclusions of our study, collaborative efforts are required to perform large international studies. 28, 29 However, it can be assumed, that multicenter studies will not be able to characterize subjects in the same detail as our monocenter study.
In conclusion, heterozygosity for the Z-allele predisposes for the development of CSPH, confirming its role as a genetic (co)factor in liver disease. Pi*ZZ/SZ patients rarely develop liver fibrosis !F3 during adulthood. However, liver fibrosis !F2 is common, which warrants the use of non-invasive methods to identify patients at risk for the development of ACLD. High BMI and GGT values identify patients with an increased pretest probability of having liver fibrosis !F2. Elevated CAP values hint at underlying hepatic steatosis, which might promote liver fibrosis progression.
